Adhesive cover occluding device for aneurysm treatment

Information

  • Patent Grant
  • 11134953
  • Patent Number
    11,134,953
  • Date Filed
    Wednesday, February 6, 2019
    6 years ago
  • Date Issued
    Tuesday, October 5, 2021
    4 years ago
Abstract
The device includes a net portion for occluding an aneurysm neck and an adhesive to secure the net portion. The device can further include a channel orifice opening in the net portion, and an agent channel for delivering a rapid-curing agent through the orifice into the aneurysm. Devices can be delivered through a catheter to the aneurysm, the net can expand to occlude the aneurysm neck, the net can be adhered to the aneurysm neck. In devices including a channel orifice and agent channel, the rapid-curing agent can be injected into the aneurysm. During injection of the rapid-curing agent, the net portion can create a barrier to inhibit the rapid-curing agent from exiting the aneurysm. After injection of the coagulation agent, portions of the treatment device, excluding the net portion, can be extracted from the patient.
Description
FIELD OF INVENTION

The present invention generally relates to medical instruments, and more particularly, to treatment devices for aneurysm therapy.


BACKGROUND

Aneurysms can be complicated and difficult to treat. For example, treatment access can be limited or unavailable when an aneurysm is located proximate critical tissues. Such factors are of particular concern with cranial aneurysms due to the brain tissue surrounding cranial vessels and the corresponding limited treatment access.


Prior solutions have included endovascular treatment access whereby an internal volume of the aneurysm sac is removed or excluded from arterial blood pressure and flow. In this respect, because the interior walls of the aneurysm can continue being subjected to flow of blood and related pressure, aneurysm rupture remains possible.


Alternative to endovascular or other surgical approaches can include occlusive devices. Such devices have typically incorporated multiple embolic coils that are delivered to the vasculature using microcatheter delivery systems. For example, when treating cranial aneurysms, a delivery catheter with embolic coils is typically first inserted into non-cranial vasculature through a femoral artery in the hip or groin area. Thereafter, the catheter is guided to a location of interest within the cranium. The sac of the aneurysm can then be filled with the embolic material to create a thrombotic mass that protects the arterial walls from blood flow and related pressure. However, such occlusive devices do have certain shortcomings, including mass effect, which can cause compression on the brain and its nerves. Obtaining an embolic coil packing density sufficient to either occlude the aneurysm neck or fill the aneurysm sac is difficult and time consuming. Further, aneurysm morphology (e.g. wide neck, bifurcation, etc.) can require ancillary devices such a stents or balloons to support the coil mass and obtain the desired packing density. The coils and accompanying ancillary devices can remain in patients for their entire lives, and can apply damaging stressing forces to the aneurysm. Current embolic coil approaches can also involve the delivery of various coils into a coil mass. With each coil inserted, there is an increased risk for an adverse event. Therefore, there is an advantage to creating a system that does not require multiple products or coils to be inserted during one procedure. Additionally, embolic coils do not always effectively treat aneurysms as re-canalization of the aneurysm and/or coil compaction can occur over time.


One particular type of occlusive approach endeavors to deliver and treat the entrance or “neck” of the aneurysm as opposed to the volume of the aneurysm by implanting a device in the parent vessel of the aneurysm. In such “neck” approaches, by minimizing blood flow across the neck, a cessation of flow into the aneurysm can be achieved. In turn, a thrombotic mass can naturally form without having to deliver embolic materials into the aneurysm sac, as previously described. However, neck-occlusive approaches, such as implanting a flow impeding device in the parent vessel, are not without drawbacks. This type of approach can impede blood flow into peripheral blood vessels while blocking the aneurysm neck in the parent vessel. Impeding flow to the peripheral blood vessel can unintentionally lead to severe damage if the openings of the vessels are blocked.


Another type of occlusive approach is to use glues, adhesives, or other similar products (e.g., NBCA (N-butyl cyanoacrylate)) to obstruct blood flow to areas of the brain. However, these products, when inserted into cranial vessels alone, can move downstream and cause embolization in areas that are not desirable. It is therefore desirable to have a device which easily, accurately, and safely occludes a neck of an aneurysm or other arterio-venous malformation in a parent vessel and can maintain the placement of any glues or adhesives used without requiring the insertion of multiple products or blocking flow into peripheral vessels communicating with the parent vessel while minimizing applied forces to the aneurysm.


It is an aim of this invention to resolve these and other issues of the art.


SUMMARY

Disclosed herein are various exemplary devices for treating an aneurysm with an adhesive cover treatment device. The devices can generally include a net portion for occluding an aneurysm neck and an adhesive to secure the net portion. The devices can further include a channel orifice opening in the net portion, and an agent channel for delivering a rapid-curing agent through the orifice into the aneurysm. Devices can be delivered through a catheter to the aneurysm, the net can expand to occlude the aneurysm neck, the net can be adhered to the aneurysm neck. In devices including a channel orifice and agent channel, the rapid-curing agent can be injected into the aneurysm. During injection of the rapid-curing agent, the net portion can create a barrier to inhibit the rapid-curing agent from exiting the aneurysm. After injection of the coagulation agent, portions of the treatment device, excluding the net portion, can be extracted from the patient.


An example treatment device for occluding an aneurysm can include a net portion that is expandable from a collapsed configuration to an occluding configuration and an adhesive for securing the net portion. The net portion in the occluding configuration can occlude an aneurysm neck to create a barrier between the aneurysm and a blood vessel. The adhesive can secure the net portion in its position in the occluding configuration near the aneurysm neck to prevent the net portion from dislodging and disrupting the barrier between the aneurysm and the blood vessel. When the barrier formed by the net portion is adhered in place, the aneurysm can self-embolize. The example device can be delivered to the aneurysm using a microcatheter.


The adhesive can be activated prior to or subsequent to the net portion reaching the occluding configuration, such as prior to delivery of the net portion to the aneurysm, upon delivery of the net portion to the aneurysm, when the net portion reaches the occluding configuration, or after the net portion reaches the occluding configuration.


An example device for occluding an aneurysm can further include a hypotube spanning at least a portion of the perimeter of the net portion that contains the adhesive in an uncured state. The hypotube can contain at least one hypotube orifice that exposes at least some of the adhesive in the uncured state to an environment outside the net portion. A curing channel can deliver a curing agent to the net portion to activate the adhesive from the uncured state. The adhesive can then adhere the net portion in the occluding configuration in its position occluding the aneurysm neck.


An example device can further include a delivery channel for delivering the adhesive to the net portion. The delivery channel can have a distal end connected to the net portion. The adhesive can be delivered to the net portion prior to or subsequent to the net portion reaching the occluding configuration, such as prior to delivery of the net portion to the aneurysm, upon delivery of the net portion to the aneurysm, when the net portion reaches the occluding configuration, or after the net portion reaches the occluding configuration.


An example device for occluding an aneurysm can further include a channel orifice and an agent channel. The channel orifice can define an opening in the net portion through which the rapid-curing agent can be injected. The channel orifice can open towards the aneurysm when the net portion is in the occluding configuration. The agent channel can be in communication with the channel orifice and can deliver the rapid-curing agent through the channel orifice into the aneurysm sac.


The agent channel can have a proximal end and a distal end. The distal end of the agent channel can communicate with the channel orifice to transfer the rapid-curing agent into the aneurysm sac. The proximal end of the agent channel can receive the rapid-curing agent. The channel orifice can also be an opening in the distal end of the agent channel, whereby a single opening functions as both the channel orifice and the distal end of the agent channel.


The example device can further include a trigger mechanism in communication with the proximal end of the agent channel. The trigger mechanism can communicate with the proximal end of the agent channel to receive the rapid-curing agent or introduce the rapid-curing agent into the agent channel. The trigger mechanism can facilitate delivery of the rapid-curing agent from the proximal end to the distal end of the agent channel, and then through the channel orifice into the aneurysm sac.


An example method for treating an aneurysm can include providing an exemplary treatment device which can include a net portion and an adhesive; delivering the exemplary treatment device to an aneurysm treatment site; expanding the net portion to an occluding configuration at an aneurysm neck to occlude at least a portion of the aneurysm neck to create a barrier between a blood vessel and the aneurysm; and adhering the net portion approximate to the aneurysm neck.


The method can further include inserting the adhesive in an uncured state into a hypotube spanning at least a portion of the perimeter of the net portion, where the hypotube contains at least one hypotube orifice exposing at least some of adhesive the environment outside the net portion; and delivering a curing agent to the net portion via a curing channel to activate the adhesive.


Another example method for treating an aneurysm can include providing an exemplary treatment device which can include a net portion, an adhesive, a channel orifice defining an opening in the net portion, and an agent channel; joining the agent channel to the channel orifice; delivering the exemplary treatment device to an aneurysm treatment site; expanding the net portion to an occluding configuration at an aneurysm neck to occlude at least a portion of the aneurysm neck to create a barrier between a blood vessel and the aneurysm to prevent a rapid-curing agent from entering the blood vessel; adhering the net portion approximate to the aneurysm neck; and delivering the rapid-curing agent through the agent channel, through the channel orifice, and into the aneurysm sac to coagulate the blood present in the aneurysm.


The method can further include providing a trigger mechanism; triggering the delivery of the agent by activating the trigger mechanism at a proximal end of the agent channel; and delivering the agent from the proximal end of the agent channel to a distal end of the agent channel.





BRIEF DESCRIPTION OF THE DRAWINGS

The above and further aspects of this invention are further discussed with reference to the following description in conjunction with the accompanying drawings, in which like numerals indicate like structural elements and features in various figures. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating principles of the invention. The figures depict one or more implementations of the inventive devices, by way of example only, not by way of limitation.



FIGS. 1a to 1c are illustrations of a treatment sequence of an exemplary treatment device to occlude an aneurysm according to aspects of the present invention;



FIGS. 2a to 2b are illustrations of a treatment sequence of an exemplary treatment device to occlude an aneurysm according to aspects of the present invention;



FIGS. 3a to 3d are illustrations of a treatment sequence of an exemplary treatment device to occlude an aneurysm and deliver a rapid-curing agent to an aneurysm according to aspects of the present invention;



FIGS. 4a to 4d are illustrations of a treatment sequence of an exemplary treatment device to occlude an aneurysm, and deliver an adhesive to a net portion and a rapid-curing agent to an aneurysm according to aspects of the present invention;



FIGS. 5a to 5g are illustrations of a treatment sequence of an exemplary treatment device to occlude an aneurysm, and deliver a curing agent to a net portion and a rapid-curing agent to an aneurysm according to aspects of the present invention;



FIGS. 6a to 6d are illustrations of a treatment sequence of an exemplary treatment device in connection with a trigger mechanism to occlude an aneurysm and deliver a rapid-curing agent to an aneurysm according to aspects of the present invention;



FIG. 7 is a flow diagram outlining example method steps that can be carried out during delivery and use of a treatment device according to aspects of the present invention; and



FIG. 8 is a flow diagram outlining example method steps that can be carried out during delivery and use of a treatment device according to aspects of the present invention.





DETAILED DESCRIPTION

The descriptions contained herein are examples of the invention and are not intended in any way to limit the scope of the invention. In general, example devices described herein describe a treatment device that can be placed and adhered over the neck of an aneurysm to create a barrier between the vessel and the aneurysm. At least one rapid-curing agent can then be delivered into the aneurysm sac. The rapid-curing agent can coagulate the blood in the aneurysm instantly.


The example devices can include a net portion that can expand from a collapsed configuration to an occluding configuration in which the net portion in the occluding configuration is shaped to occlude an aneurysm neck. The net portion can be adhered in position to occlude the aneurysm neck. In the occluding configuration, the net portion can generally have a channel orifice working in connection with an agent channel that delivers a rapid-curing agent through the channel orifice and into the aneurysm sac.


It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. By “comprising” or “containing” or “including” it is meant that at least the named compound, element, particle, or method step is present in the composition or article or method, but does not exclude the presence of other compounds, materials, particles, method steps, even if the other such compounds, material, particles, method steps have the same function as what is named.


In describing examples, terminology will be resorted to for the sake of clarity. It is intended that each term contemplates its broadest meaning as understood by those skilled in the art and includes all technical equivalents that operate in a similar manner to accomplish a similar purpose. It is also to be understood that the mention of one or more steps of a method does not preclude the presence of additional method steps or intervening method steps between those steps expressly identified. Steps of a method can be performed in a different order than those described herein without departing from the scope of the disclosed technology. Similarly, it is also to be understood that the mention of one or more components in a device or system does not preclude the presence of additional components or intervening components between those components expressly identified.



FIGS. 1a through 1c are illustrations of stages or steps that can occur during a treatment sequence of an exemplary treatment device 100 delivered to an aneurysm 10. FIG. 1a is an illustration of an example treatment device 100 wherein a net portion 102 is shown in a collapsed delivery configuration inside a delivery catheter 400. The net portion 102 can have an adhesive agent 108 located on at least a portion of the outer perimeter of the net portion 102, and an adhesive barrier 110 covering the adhesive agent 108. The net portion 102 can be sized to fit within the lumen of a delivery catheter 400 when the net portion 102 is in the collapsed configuration. When the net portion 102 is in the collapsed configuration, the net portion 102 can have sufficient flexibility to be delivered through the delivery catheter 400, navigating torturous anatomical geometries, to be delivered to an aneurysm 10. The net portion 102 in the collapsed configuration can have a substantially tubular shape.


Moving on to FIG. 1b, the treatment device 100 can be delivered to an aneurysm 10 by sliding the device 100 distally when the net portion 102 is in a collapsed configuration through a delivery catheter 400. The treatment device 100 can be delivered to a treatment site through a blood vessel 106. FIG. 1b illustrates the treatment device 100 inside the delivery catheter 400 located near an aneurysm neck 12. FIG. 1b further shows the net portion 102 pushed partially out of the delivery catheter 400 for deployment inside the aneurysm sac 16. The net portion 102 can expand as it exits the delivery catheter 400. The net portion 102 can include a memory shape material such as Nitinol, a Nitinol alloy, a polymer memory shape material, or other memory shape material having properties for reshaping as described herein. The net portion 102 can be in a deformed shape in the collapsed configuration and reshape based on a predetermined shape after exiting the delivery catheter 400. As shown here, upon the net portion 102 exiting the delivery catheter 400, the adhesive barrier 110 can be removed to expose the adhesive agent 108 located on at least a portion of the perimeter of the net portion. Alternatively, the adhesive barrier 110 can be removed at other times prior to or subsequent to the net portion 102 reaching the occluding configuration, such as prior to delivery of the net portion 102 to the aneurysm 10, upon delivery of the net portion 102 to the aneurysm 10, when the net portion 102 reaches the occluding configuration, or after the net portion 102 reaches the occluding configuration. The adhesive agent 108 can include medical grade silicone-based adhesives as well as light-curable adhesives. The adhesive agent 108 can include adhesives such as N-butyl cyanoacrylate (NBCA), Poly(methyl methacrylate) (PMMA996), N-Methyl-2-Pyrrolidone (NMP), Carbonic anhydrase-related protein 10 (CA10), EA/MMA, and DME.



FIG. 1c illustrates the example treatment device 100 wherein the net portion 102 is in an occluding configuration in the aneurysm 10. The net portion 102 in the occluding configuration can be sized to occlude at least a portion of an aneurysm neck 12. The net portion 102 in the occluding configuration can completely occlude the aneurysm neck 12 as depicted in FIG. 1c. The net portion 102 in the occluding configuration can occlude the neck 12 to create a barrier between a blood vessel 106 and the aneurysm 10. The net portion 102 can occlude the aneurysm 10 from inside the aneurysm sac 16. As illustrated in FIG. 1c, the exposed adhesive agent 108 can be in contact with the aneurysm wall 14 when the net portion 102 is in the occluding configuration. In occluding configuration, the net portion 102 can be capable of deflecting a blood flow from the aneurysm 10, diverting a blood flow from the aneurysm 10, slowing a blood flow into the aneurysm 10, or any combination thereof.


In the occluding configuration, the net portion 102 can extend to the aneurysm wall 14, and the adhesive agent 108 can hold the net portion 102 in its position relative to the aneurysm wall 14 and aneurysm neck 12 such that the treatment device 100 doesn't become dislodged and therefore ineffective at inhibiting blood flow into the aneurysm 10. The net portion 102 can also provide a force against the aneurysm wall 14 to help maintain the occluding configuration of the net portion 102 and assist the adhesive agent 108 in adhering to the aneurysm wall 14. For example, the net portion 102 can be made of a memory shape material having a first, predetermined shape and a second, collapsed shape in the collapsed configuration. When the net portion 102 is in an occluding configuration within the aneurysm 10, the net portion 102 can move to a third, deployed shape that is based at least in part on the first, predetermined shape and the anatomical geometry of the aneurysm 10. In the example, the first, predetermined shape can be sized larger than the wall 14 within the aneurysm sac 16; the net portion 102 can move to extend to the wall 14; and the net portion 102 can provide a force against the wall 14 as the properties of the memory shape material cause the net portion 102 to attempt to open to the predetermined shape. This force can help the adhesive agent 108 adhere to the wall to maintain the position of the net portion 102. The net portion 102 in the occluding configuration can take the shape of the aneurysm neck 12 and/or interior walls 14 of the aneurysm near the aneurysm neck 12.



FIG. 2a illustrates the deployment of the net portion 102 in the same manner described in FIG. 1b. FIG. 2a, however, shows the net portion 102 pushed partially out of the delivery catheter 400 for deployment outside the aneurysm sac 16 across the aneurysm neck 12. FIG. 2b illustrates the example treatment device 100 wherein the net portion 102 is in an occluding configuration outside of the aneurysm 10. In this example, the adhesive agent 108 can adhere the net portion 102 to the walls of the blood vessel 106 and over the aneurysm neck 12 to deflect a blood flow from the aneurysm 10, divert a blood flow from the aneurysm 10, slow a blood flow into the aneurysm 10, or any combination thereof. The adhesive agent 108 can hold the net portion 102 in its position over the aneurysm neck 12 such that the treatment device 100 doesn't become dislodged and therefore ineffective at inhibiting blood flow into the aneurysm 10 and becoming a potential blockage elsewhere in the vascular.



FIGS. 3a through 3c are illustrations of stages or steps that can occur during a treatment sequence of an exemplary treatment device 100 to occlude an aneurysm and deliver a rapid-curing agent 114 to an aneurysm 10. FIG. 3a is an illustration of an example treatment device 100 wherein the net portion 102 with an adhesive agent 108 covered by an adhesive barrier 110 is shown in a collapsed delivery configuration inside a delivery catheter 400, similar to FIG. 1a. The net portion 102 can contain a channel orifice 104 positioned on a proximal end of the collapsed net portion 102. The channel orifice 104 can work in connection with an agent channel 112. The channel orifice 104 can be connected to the distal end 112a of the agent channel 112. The treatment device 100 can be sized to fit within the lumen of a delivery catheter 400 when the net portion 102 is in the collapsed configuration. The agent channel 112 can have sufficient length to be accessible outside of the patient when the net portion 102 reaches a treatment site. The net portion 102 is shown in a collapsed delivery configuration inside a delivery catheter 400.



FIG. 3b illustrates the treatment device 100 inside the delivery catheter 400 with the net portion 102 exiting the delivery catheter 400 for deployment outside a sac 16 of an aneurysm 10, similar to the manner described in FIG. 1b. Alternatively, the net portion 102 can deploy inside the sac 16 of the aneurysm 10. As the device 100 exits the delivery catheter 400, the adhesive agent 108 is exposed in the manner described in FIG. 1b.



FIG. 3c illustrates the treatment device 100 wherein the net portion 102 is in the occluding configuration outside the aneurysm sac 16 similar to FIG. 2b. As illustrated, the channel orifice 104 can be located in the net portion 102 such that the channel orifice 104 opens up to the aneurysm 10. The channel orifice 104 can be centrally located in the net portion 102. The channel orifice 104 in the net portion 102 can work in connection with an agent channel 112. The agent channel 112 can allow for the transfer of one or more rapid-curing agents 114 through the channel 112 to the channel orifice 104. The rapid-curing agent 114 can include agents such as collagen, chitosan, kaolin, zeolite, organic or biocompatible solvents, or other agents having properties for rapid-curing as described herein. The agent channel 112 can have a distal end 112a and a proximal end 112b (see FIG. 6). The distal end 112a of the agent channel 112 can connect to the channel orifice 104. The proximal end 112b can receive the rapid-curing agent 114 into the agent channel 112 and deliver the rapid-curing agent 114 from the proximal end to the distal end 112a connected to the channel orifice 104. The proximal end 112b can be accessible outside of the patient for injection of the rapid-curing agent 114 into the patient. Rapid-curing agent 114 passing through the lumen of the agent channel 112 to the distal end 112a can subsequently pass through the channel orifice 104 and into the aneurysm sac 16 upon reaching the distal end 112a of the agent channel 112. The distal end 112a of the agent channel 112 can also be the channel orifice 104 of the net portion 102. The rapid-curing agent 114 can coagulate the blood inside the aneurysm 10. The rapid-curing agent 114 can coagulate the blood inside the aneurysm 10 virtually instantaneously upon contacting the blood inside the aneurysm 10 according to the coagulation properties of the rapid-curing agent 114.


As shown in FIG. 3d, once the rapid-curing agent 114 has been pumped into the aneurysm sac 16, the components of the treatment device 100 (not shown) aside from the net portion 102 can be removed from the aneurysm 10. The components of the treatment device 100 aside from the net portion 102 can be removed once the rapid-curing agent 114 has coagulated the blood in the aneurysm 10. The components of the treatment device 100 aside from the net portion 102 can be sized to traverse through a lumen of a retrieval catheter (not shown).



FIGS. 4a to 4d are illustrations of stages or steps that can occur during a treatment sequence of an exemplary treatment device 100 to occlude an aneurysm 10, deliver an adhesive 108 to the net portion 102, and deliver a rapid-curing agent 114 to an aneurysm 10. FIG. 4a is an illustration of an example treatment device 100 wherein the net portion 102 is shown in a collapsed delivery configuration inside a delivery catheter 400. The device 100 can have a channel orifice 104 and agent channel 112 as described in FIG. 3a. The device 100 can also have a delivery channel 118 that can work in communication with the net portion 102. The delivery channel 118 can have a distal end 118a in communication with the net portion 102. The delivery channel 108 can deliver adhesive 108 the net portion 102 to adhere the net portion 102 approximate the neck 12. The treatment device 100 can be sized to fit within the lumen of a delivery catheter 400 when the net portion 102 is in the collapsed configuration.



FIG. 4b illustrates the deployment of the net portion 102 inside the sac 16 of an aneurysm 10. As illustrated in FIG. 4b, the treatment device 100 can be delivered to an aneurysm 10 by sliding the device 100 distally when the net portion 102 is in a collapsed configuration through a delivery catheter 400. The treatment device 100 can be delivered to a treatment site through a blood vessel 106. FIG. 4b illustrates the treatment device 100 inside the delivery catheter 400 located near an aneurysm neck 12. FIG. 4b further shows the net portion 102 pushed partially out of the delivery catheter 400 for deployment inside the aneurysm sac 16. The net portion 102 can expand as it exits the delivery catheter 400. Alternatively, the net portion 102 can deploy outside the sac 16 of the aneurysm 10.



FIG. 4c illustrates the treatment device 100 wherein the net portion 102 is in the occluding configuration inside the aneurysm sac 16. As shown in FIG. 4c, after the net portion 102 reaches the occluding configuration, the adhesive agent 108 can be delivered to the net portion 102 through the delivery channel 118 to adhere the net portion 102 over the aneurysm neck 12 inside the aneurysm sac 16. Alternatively, delivery channel 118 can deliver adhesive 108 to the net portion 102 to adhere the net portion 102 in the occluding configuration over the aneurysm neck 12 outside the aneurysm sac 16. The adhesive 108 can also be delivered prior to or subsequent to the net portion 102 reaching the occluding configuration, such as prior to delivery of the net portion 102 to the aneurysm 10, upon delivery of the net portion 102 to the aneurysm 10, or when the net portion 102 reaches the occluding configuration. After the net portion 102 is adhered over the neck 12, the rapid-curing agent 114 can be delivered to the aneurysm sac 16 in the manner described in FIG. 3c.


As in FIG. 3d, FIG. 4d illustrates the aneurysm 10 once the rapid-curing agent 114 has been pumped into the aneurysm sac 16, after which the components of the treatment device 100 (not shown) aside from the net portion 102 can be removed from the aneurysm 10.



FIGS. 5a to 5f are illustrations of stages or steps that can occur during a treatment sequence of an exemplary treatment device 100 to occlude an aneurysm 10, deliver a curing agent 124 to the net portion 102, and deliver a rapid-curing agent 114 to an aneurysm 10. FIG. 5a is an illustration of an example treatment device 100 wherein the net portion 102 is shown in a collapsed delivery configuration inside a delivery catheter 400. The device 100 can have a channel orifice 104 and agent channel 112 as described in FIG. 3a. The device 100 can also have a hypotube 120 spanning at least a portion of the perimeter of the net portion 102. The hypotube 120 can span the entire perimeter of the net portion 102. The hypotube 120 can contain an adhesive 108 in an uncured state. The hypotube 120 can contain one or more hypotube orifices 122 (see FIG. 5d) that expose the uncured adhesive 108 to the environment outside the hypotube 120.


The device 100 can further have a curing channel 126 that can work in communication with the net portion 102. The curing channel 126 can have a distal end 126a in connection with net portion 102. The curing channel 126 can deliver a curing agent (as discussed above) to the net portion 102 of the device 100. The curing agent 126 can activate the uncured adhesive 108 in the net portion 102. The treatment device 100 in its entirety can be sized to fit within the lumen of a delivery catheter 400 when the net portion 102 is in the collapsed configuration.



FIG. 5b illustrates the deployment of the net portion 102 inside the sac 16 of an aneurysm 10 similar to FIG. 4b. FIG. 5c illustrates the treatment device 100 wherein the net portion 102 is in the occluding configuration inside the aneurysm sac 16 in the manner shown in FIG. 4c. As shown here, after the net portion 102 reaches the occluding configuration, the curing agent 124 can be delivered to the net portion 102 through the curing channel 126 to activate the adhesive agent 108 and adhere the net portion 102 over the aneurysm neck 12 inside the aneurysm sac 16. Alternatively, the curing agent 124 can be delivered to the net portion 102 through the curing channel 126 to activate the adhesive agent 108 and adhere the net portion 102 over the aneurysm neck 12 outside the aneurysm sac 16. The curing agent 124 can be delivered prior to or subsequent to the net portion 102 reaching the occluding configuration, such as prior to delivery of the net portion 102 to the aneurysm 10, upon delivery of the net portion 102 to the aneurysm 10, or when the net portion 102 reaches the occluding configuration.



FIG. 5d shows a blown-up and cross-sectional view of the hypotube 120. The hypotube 120 can contain at least one hypotube orifice 122 as well as the adhesive 108 in an uncured state. The hypotube orifices 122 can expose the uncured adhesive 108 to the environment outside the hypotube 120. FIG. 5e is a cross section of net portion 102 loaded with adhesive 108. For example, in FIGS. 5d and 5e, the uncured adhesive 108 can be delivered by first being mechanically held within the net portion 102. The net portion 102 can contain a lumen along the circumference (a hypotube 122) with orifices that allow the uncured adhesive to be exposed. The viscosity of the adhesive 108 can be characterized such that it could be injected into a lumen of the net portion 102 but viscous enough that it will not relocate or disperse during delivery. Upon placing the net portion 102 and later delivering a curing agent, the adhesive within the net will be activated. The net would have orifices that expose some of the adhesive to the aneurysm, allowing it to adhere the edges of the net to the aneurysm wall. In this case, the net would act as the device blocking flow into the aneurysm



FIG. 5f illustrates the treatment device 100 wherein the net portion 102 is in the occluding configuration inside the aneurysm sac 16 in the manner shown in FIG. 4c. When the curing agent 124 is delivered to the net portion 102, the adhesive 108 can cure and adhere the net portion 102 in the occluding configuration over the aneurysm neck 12 to occlude the aneurysm 10. Once the net portion 102 has been adhered in position, the rapid curing agent 114 can be delivered to the aneurysm 10 as illustrated in FIG. 3c


Similar to FIG. 3d, FIG. 5g illustrates the aneurysm 10 once the rapid-curing agent 114 has been pumped into the aneurysm sac 16, after which the components of the treatment device 100 aside from the net portion 102 are removed from the aneurysm 10.



FIGS. 6a to 6e are illustrations of stages or steps that can occur during another example implementation sequence of an exemplary treatment device 100 to occlude an aneurysm 10 and deliver a rapid-curing agent 114 to an aneurysm 10.



FIG. 6a is an illustration of an example treatment device 100 including a net portion 102, a channel orifice 104, an agent channel 112, and a trigger mechanism 116. The net portion 102 is shown in a collapsed delivery configuration inside a delivery catheter 400. The net portion 102 can contain the channel orifice 104 that can be in communication with an agent channel 112. The agent channel 112 can have a proximal end 112b in communication with the trigger mechanism 116. The proximal end 112b of the agent channel 112 can receive the rapid-curing agent 114 into the agent channel 112 for delivery. The trigger mechanism 116 can facilitate the delivery of the rapid-curing agent 114 to an aneurysm sac 16. The components of the treatment device 100 excluding the trigger mechanism 116 can be sized to fit within the lumen of a delivery catheter 400 when the net portion 102 is in the collapsed configuration.



FIG. 6b illustrates the treatment device 100 inside the delivery catheter 400 with the net portion 102 exiting the delivery catheter 400 for deployment outside the aneurysm sac 16 in a manner similar to FIG. 4b. As illustrated in FIGS. 6b to 6d, the treatment site can include an aneurysm 10 positioned adjacent bifurcated blood vessel branches and the treatment device 100 can be delivered to the aneurysm 10 through a stem branch 106 feeding the bifurcated blood vessel branches.



FIG. 6c illustrates the treatment device 100 wherein the net portion 102 is in an occluding configuration in the aneurysm 10. Upon the net portion 102 reaching the occluding configuration, the trigger mechanism 116 can facilitate the delivery of the rapid-curing agent 114 through the agent channel 112 to the aneurysm sac 16.


As in FIG. 3d, FIG. 6d illustrates the aneurysm 10 once the rapid-curing agent 114 has been pumped into the aneurysm sac 16, after which the components of the treatment device 100 aside from the net portion 102 can be removed from the aneurysm 10.



FIG. 7 is a flow diagram outlining example method steps that can be carried out during the administration of a treatment device 100. The method steps can be implemented by any of the example means described herein or by any means that would be known to one of ordinary skill in the art.


Referring to a method 700 outlined in FIG. 7, in step 710 a treatment device comprising a net portion and an adhesive can be provided for administration to a patient. In step 720, the treatment device can be delivered to the aneurysm treatment site. In step 730, the net portion can be expanded to an occluding configuration approximate a center of an aneurysm neck, wherein the expanded net portion occludes at least a portion of the aneurysm neck to create a barrier between a blood vessel and the aneurysm. In step 740, the net portion can be adhered approximate to the aneurysm neck.


Method 700 can further comprise the steps of inserting the adhesive in an uncured state into a hypotube spanning at least a portion of the perimeter of the net portion, wherein the hypotube comprises at least one hypotube orifice exposing a portion of the adhesive in the uncured state to the environment outside the net portion, and delivering a curing agent to the net portion via a curing channel to activate the adhesive.



FIG. 8 is a flow diagram outlining example method steps that can be carried out during the administration of a treatment device 100. The method steps can be implemented by any of the example means described herein or by any means that would be known to one of ordinary skill in the art.


Referring to a method 800 outlined in FIG. 8, in step 810 the treatment device comprising a net portion, an adhesive, a channel orifice defining an opening in the net portion, and an agent channel can be provided for administration to a patient. In step 820, the agent channel can be joined to communicate with the channel orifice. In step 830, the treatment device can be delivered to an aneurysm treatment site. In step 840, the net portion can be expanded to the occluding configuration approximate a center of an aneurysm neck. When the net portion is expanded to the occluding configuration in step 840, the net portion can occlude at least a portion of an aneurysm neck. Step 840 can also create a barrier between a blood vessel 106 and the aneurysm to prevent the rapid-curing agent from entering the blood vessel. In step 850, net portion can be adhered approximate to the aneurysm neck. In step 860, the rapid-curing agent can be delivered through the agent channel and the channel orifice into the aneurysm sac to coagulate the blood present in the aneurysm.


Method 800 can further comprise the steps of providing a trigger mechanism and triggering the delivery of the agent by activating the trigger mechanism at a proximal end of the agent channel to deliver the agent from the proximal end of the agent channel to a distal end of the agent channel.


It should be apparent to those skilled in the art that the present teachings cover devices with any possible combination of a net portion, adhesive, channel orifice, agent channel, hypotube, delivery channel, curing channel, and/or trigger mechanism. The descriptions contained herein are examples of the invention and are not intended in any way to limit the scope of the invention. As described herein, the invention contemplates many variations and modifications of the device for occluding an aneurysm, including alternative geometries of elements and components described herein, utilizing any number of known means for braiding, knitting, weaving, or otherwise forming the net portion as is known in the art, utilizing any of numerous materials for each component or element (e.g. radiopaque materials, memory shape materials, etc.), utilizing additional components including components to deliver a treatment device to an aneurysm or eject an treatment device from a delivery catheter, or utilizing additional components to perform functions not described herein, for example. These modifications would be apparent to those having ordinary skill in the art to which this invention relates and are intended to be within the scope of the claims which follow.

Claims
  • 1. A treatment device for treating an aneurysm comprising: a net portion expandable from a collapsed configuration to an occluding configuration, the occluding configuration sized to extend across and occlude at least a portion of a neck of the aneurysm to create a barrier between a blood vessel and the aneurysm;an adhesive circumscribing at least a portion of a perimeter of the net portion when the net portion is in the occluding configuration, the adhesive being positioned to contact with tissue approximate the aneurysm neck thereby securing the net portion in a position approximate the aneurysm neck; anda hypotube containing the adhesive in an uncured state and circumscribing at least a portion of the perimeter of the net portion when the net portion is in the occluding configuration, the hypotube comprising at least one orifice configured to expose a portion of the adhesive in the uncured state to the tissue approximate the aneurysm neck.
  • 2. The treatment device of claim 1 wherein the net portion in the collapsed configuration is sized to traverse through a lumen of a delivery catheter.
  • 3. The treatment device of claim 1 wherein the adhesive is activated subsequent to the net portion reaching the occluding configuration.
  • 4. The treatment device of claim 1 wherein the adhesive is activated prior to the net portion reaching the occluding configuration.
  • 5. The treatment device of claim 4 further comprising a delivery channel delivering the adhesive to the net portion, the delivery channel comprising a distal end connected to the net portion.
  • 6. The treatment device of claim 5 wherein the adhesive is delivered to the net portion through the delivery channel prior to the net portion reaching the occluding configuration.
  • 7. The treatment device of claim 5 wherein the adhesive is delivered to the net portion through the delivery channel subsequent to the net portion reaching the occluding configuration.
  • 8. The treatment device of claim 4 further comprising: a channel orifice defining an opening in the net portion, wherein in the occluding configuration the channel orifice is open to the aneurysm; andan agent channel in communication with the channel orifice delivering a rapid-curing agent to an aneurysm sac through the channel orifice.
  • 9. The treatment device of claim 8 further comprising: a trigger mechanism for introducing the rapid-curing agent into the agent channel; wherein the agent channel comprises a proximal end in communication with the trigger mechanism to receive the rapid-curing agent into the agent channel and a distal end in communication with the channel orifice; andwherein the agent channel delivers the rapid-curing agent from the proximal end to the distal end and through the channel orifice into the sac of the aneurysm.
  • 10. The treatment device of claim 8 wherein the adhesive is activated prior to the net portion reaching the occluding configuration.
  • 11. The treatment device of claim 8 wherein the adhesive is activated subsequent to the net portion reaching the occluding configuration.
  • 12. The treatment device of claim 8 further comprising a delivery channel delivering the adhesive to the net portion, the delivery channel comprising a distal end connected to the net portion.
  • 13. The treatment device of claim 12 wherein the adhesive is delivered to the net portion through the delivery channel prior to the net portion reaching the occluding configuration.
  • 14. The treatment device of claim 12 wherein the adhesive is delivered to the net portion through the delivery channel subsequent to the net portion reaching the occluding configuration.
  • 15. The treatment device of claim 12 further comprising: a trigger mechanism for introducing the rapid-curing agent into the agent channel; wherein the agent channel comprises a proximal end in communication with the trigger mechanism to receive the rapid-curing agent into the agent channel and a distal end in communication with the channel orifice; andwherein the agent channel delivers the rapid-curing agent from the proximal end to the distal end and through the channel orifice into the sac of the aneurysm.
  • 16. A method for treating an aneurysm comprising providing a treatment device comprising a net portion and an adhesive;delivering the treatment device to an aneurysm treatment site;expanding the net portion to an occluding configuration approximate a center of an aneurysm neck, wherein the expanded net portion occludes at least a portion of the aneurysm neck to create a barrier between a blood vessel and the aneurysm;inserting the adhesive in an uncured state into a hypotube circumscribing at least the portion of a perimeter of the net portion, wherein the hypotube comprises at least one hypotube orifice configured to expose a portion of the adhesive in the uncured state to tissue approximate the aneurysm neck;delivering a curing agent to the net portion via a curing channel to activate the adhesive; andadhering the net portion approximate to the aneurysm neck by the adhesive.
  • 17. A method for treating an aneurysm comprising: providing a treatment device comprising a net portion, a hypotube circumscribing at least a portion of a perimeter of the net portion when the net portion is in an occluding configuration, a channel orifice defining an opening in the net portion, and an agent channel;joining the agent channel with the channel orifice;delivering the treatment device to an aneurysm treatment site;expanding the net portion to the occluding configuration approximate a center of an aneurysm neck, wherein the expanded net portion occludes at least a portion of the aneurysm neck to create a barrier between a blood vessel and the aneurysm to prevent a rapid-curing agent from entering the blood vessel;adhering the net portion approximate to the aneurysm neck by an adhesive delivered, in an uncured state, through the hypotube such that the adhesive exits the hypotube through at least one orifice of the hypotube and, upon exiting the hypotube, the adhesive contacts tissue approximate the aneurysm neck; anddelivering the rapid-curing agent through the agent channel and the channel orifice into the aneurysm sac to coagulate the blood present in the aneurysm.
  • 18. The method of claim 17 further comprising the steps of: providing a trigger mechanism;triggering the delivery of the rapid-curing agent by activating the trigger mechanism at a proximal end of the agent channel; anddelivering the agent from the proximal end of the agent channel to a distal end of the agent channel.
US Referenced Citations (412)
Number Name Date Kind
2849002 Oddo Aug 1958 A
3480017 Shute Nov 1969 A
4085757 Pevsner Apr 1978 A
4282875 Serbinenko et al. Apr 1981 A
4364392 Strother et al. Dec 1982 A
4395806 Wonder et al. Aug 1983 A
4517979 Pecenka May 1985 A
4545367 Tucci Oct 1985 A
4836204 Landymore et al. Jun 1989 A
4991602 Amplatz et al. Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5025060 Yabuta et al. Jun 1991 A
5065772 Cox, Jr. Nov 1991 A
5067489 Lind Nov 1991 A
5122136 Guglielmi et al. Jun 1992 A
5192301 Kamiya et al. Mar 1993 A
5261916 Engelson Nov 1993 A
5304195 Twyford, Jr. et al. Apr 1994 A
5334210 Gianturco Aug 1994 A
5350397 Palermo Sep 1994 A
5423829 Pham et al. Jun 1995 A
5624449 Pham et al. Apr 1997 A
5645558 Horton Jul 1997 A
5733294 Forber et al. Mar 1998 A
5891128 Chin et al. Apr 1999 A
5916235 Guglielmi Jun 1999 A
5928260 Chin et al. Jul 1999 A
5935148 Villar Aug 1999 A
5941249 Maynard Aug 1999 A
5951599 McCrory Sep 1999 A
5964797 Ho Oct 1999 A
6007573 Wallace et al. Dec 1999 A
6024756 Pham Feb 2000 A
6036720 Abrams Mar 2000 A
6063070 Eder May 2000 A
6063100 Diaz et al. May 2000 A
6063104 Villar May 2000 A
6080191 Thaler Jun 2000 A
6086577 Ken et al. Jul 2000 A
6096021 Helm et al. Aug 2000 A
6113609 Adams Sep 2000 A
6123714 Gia et al. Sep 2000 A
6168615 Ken Jan 2001 B1
6168622 Mazzocchi Jan 2001 B1
6193708 Ken et al. Feb 2001 B1
6221086 Forber Apr 2001 B1
6270515 Linden et al. Aug 2001 B1
6315787 Tsugita et al. Nov 2001 B1
6331184 Abrams Dec 2001 B1
6334048 Edvardsson et al. Dec 2001 B1
6346117 Greenhalgh Feb 2002 B1
6350270 Roue Feb 2002 B1
6375606 Garbaldi et al. Apr 2002 B1
6375668 Gifford Apr 2002 B1
6379329 Naglreiter et al. Apr 2002 B1
6391037 Greenhalgh May 2002 B1
6419686 McLeod et al. Jul 2002 B1
6428558 Jones Aug 2002 B1
6454780 Wallace Sep 2002 B1
6463317 Kucharczyk et al. Oct 2002 B1
6506204 Mazzocchi Jan 2003 B2
6527919 Roth Mar 2003 B1
6547804 Porter et al. Apr 2003 B2
6551303 Van Tassel Apr 2003 B1
6569179 Teoh May 2003 B2
6569190 Whalen, II et al. May 2003 B2
6572628 Dominguez Jun 2003 B2
6589230 Gia et al. Jul 2003 B2
6589256 Forber Jul 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6620152 Guglielmi Sep 2003 B2
6669719 Wallace et al. Dec 2003 B2
6689159 Lau et al. Feb 2004 B2
6746468 Sepetka Jun 2004 B1
6780196 Chin et al. Aug 2004 B2
6802851 Jones Oct 2004 B2
6811560 Jones Nov 2004 B2
6833003 Jones et al. Dec 2004 B2
6846316 Abrams Jan 2005 B2
6849081 Sepetka et al. Feb 2005 B2
6855154 Abdel-Gawwad Feb 2005 B2
6949116 Solymar et al. Sep 2005 B2
6964657 Cragg et al. Nov 2005 B2
6964671 Cheng Nov 2005 B2
6994711 Hieshima et al. Feb 2006 B2
7044134 Khairkhahan et al. May 2006 B2
7083632 Avellanet Aug 2006 B2
7093527 Rapaport et al. Aug 2006 B2
7128736 Abrams et al. Oct 2006 B1
7152605 Khairkhahan et al. Dec 2006 B2
7153323 Teoh Dec 2006 B1
7195636 Avellanet et al. Mar 2007 B2
7229454 Tran et al. Jun 2007 B2
7229461 Chin et al. Jun 2007 B2
7309345 Wallace Dec 2007 B2
7371249 Douk et al. May 2008 B2
7410482 Murphy et al. Aug 2008 B2
7572288 Cox Aug 2009 B2
7597704 Frazier et al. Oct 2009 B2
7608088 Jones Oct 2009 B2
7695488 Berenstein et al. Apr 2010 B2
7713264 Murphy May 2010 B2
7744652 Morsi Jun 2010 B2
7892248 Tran Feb 2011 B2
7985238 Balgobin et al. Jul 2011 B2
RE42758 Ken Sep 2011 E
8016852 Ho Sep 2011 B2
8021416 Abrams Sep 2011 B2
8025668 McCartney Sep 2011 B2
8034061 Amplatz et al. Oct 2011 B2
8048145 Evans et al. Nov 2011 B2
8062325 Mitelberg et al. Nov 2011 B2
8075585 Lee et al. Dec 2011 B2
8142456 Rosqueta et al. Mar 2012 B2
8221483 Ford et al. Jul 2012 B2
8261648 Marchand et al. Sep 2012 B1
8267923 Murphy Sep 2012 B2
8361106 Solar et al. Jan 2013 B2
8361138 Adams Jan 2013 B2
8372114 Hines Feb 2013 B2
8398671 Chen Mar 2013 B2
8430012 Marchand Apr 2013 B1
8454633 Amplatz et al. Jun 2013 B2
8523897 van der Burg et al. Sep 2013 B2
8523902 Heaven et al. Sep 2013 B2
8551132 Eskridge et al. Oct 2013 B2
8777974 Amplatz et al. Jul 2014 B2
8900304 Alobaid Dec 2014 B1
8992568 Duggal et al. Mar 2015 B2
8998947 Aboytes et al. Mar 2015 B2
8974512 Aboytes et al. Apr 2015 B2
9055948 Jaeger et al. Jun 2015 B2
9107670 Hannes Aug 2015 B2
9161758 Figulla et al. Oct 2015 B2
9232992 Heidner et al. Jan 2016 B2
9259337 Cox et al. Feb 2016 B2
9314326 Wallace et al. Apr 2016 B2
9351715 Mach May 2016 B2
9414842 Glimsdale et al. Aug 2016 B2
9526813 Cohn et al. Dec 2016 B2
9532792 Galdonik et al. Jan 2017 B2
9532873 Kelley Jan 2017 B2
9533344 Monetti et al. Jan 2017 B2
9539011 Chen et al. Jan 2017 B2
9539022 Bowman Jan 2017 B2
9539122 Burke et al. Jan 2017 B2
9539382 Nelson Jan 2017 B2
9549830 Bruszewski et al. Jan 2017 B2
9554805 Tompkins et al. Jan 2017 B2
9561096 Fogarty Feb 2017 B2
9561125 Bowman et al. Feb 2017 B2
9572982 Burnes et al. Feb 2017 B2
9579104 Beckham et al. Feb 2017 B2
9579484 Barnell Feb 2017 B2
9585642 Dinsmoor et al. Mar 2017 B2
9585669 Becking et al. Mar 2017 B2
9615832 Bose et al. Apr 2017 B2
9615951 Bennett et al. Apr 2017 B2
9622753 Cox Apr 2017 B2
9629635 Hewitt et al. Apr 2017 B2
9636115 Henry et al. May 2017 B2
9636439 Chu et al. May 2017 B2
9642675 Werneth et al. May 2017 B2
9655633 Leynov et al. May 2017 B2
9655645 Staunton May 2017 B2
9655989 Cruise et al. May 2017 B2
9662129 Galdonik et al. May 2017 B2
9662238 Dwork et al. May 2017 B2
9662425 Lilja et al. May 2017 B2
9668898 Wong Jun 2017 B2
9675477 Thompson Jun 2017 B2
9675782 Connolly Jun 2017 B2
9676022 Ensign Jun 2017 B2
9681861 Heisel et al. Jun 2017 B2
9692557 Murphy Jun 2017 B2
9693852 Lam et al. Jul 2017 B2
9700262 Janik et al. Jul 2017 B2
9700399 Acosta-Acevedo Jul 2017 B2
9717421 Griswold et al. Aug 2017 B2
9717500 Tieu et al. Aug 2017 B2
9717502 Teoh et al. Aug 2017 B2
9724103 Cruise et al. Aug 2017 B2
9724526 Strother et al. Aug 2017 B2
9750565 Bloom et al. Sep 2017 B2
9757260 Greenan Sep 2017 B2
9764111 Gulachenski Sep 2017 B2
9770251 Bowman et al. Sep 2017 B2
9770577 Li et al. Sep 2017 B2
9775621 Tompkins et al. Oct 2017 B2
9775706 Paterson et al. Oct 2017 B2
9775732 Khenansho Oct 2017 B2
9788800 Mayoras, Jr. Oct 2017 B2
9795391 Saatchi et al. Oct 2017 B2
9801980 Karino et al. Oct 2017 B2
9808599 Bowman et al. Nov 2017 B2
9833252 Sepetka et al. Dec 2017 B2
9833604 Lam et al. Dec 2017 B2
9833625 Waldhauser et al. Dec 2017 B2
9918720 Marchand et al. Mar 2018 B2
9955976 Hewitt et al. May 2018 B2
10130372 Griffin Nov 2018 B2
10307148 Heisel et al. Jun 2019 B2
10327781 Divino et al. Jun 2019 B2
10342546 Sepetka et al. Jul 2019 B2
10517604 Bowman et al. Dec 2019 B2
10716573 Connor Jul 2020 B2
20020068974 Kuslich et al. Jun 2002 A1
20020082638 Porter et al. Jun 2002 A1
20020143349 Gifford, III et al. Oct 2002 A1
20020147497 Belef et al. Oct 2002 A1
20020188314 Anderson et al. Dec 2002 A1
20030028209 Teoh et al. Feb 2003 A1
20030120337 Van Tassel et al. Jun 2003 A1
20030171739 Murphy Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030181927 Wallace Sep 2003 A1
20030181945 Opolski Sep 2003 A1
20030195553 Wallace Oct 2003 A1
20030216772 Konya Nov 2003 A1
20040034366 van der Burg et al. Feb 2004 A1
20040034386 Fulton et al. Feb 2004 A1
20040044391 Porter Mar 2004 A1
20040087998 Lee et al. May 2004 A1
20040098027 Teoh et al. May 2004 A1
20040127935 Van Tassel et al. Jul 2004 A1
20040133222 Tran et al. Jul 2004 A1
20040153120 Seifert et al. Aug 2004 A1
20040210297 Lin et al. Oct 2004 A1
20040254594 Alfaro Dec 2004 A1
20050021016 Malecki et al. Jan 2005 A1
20050021072 Wallace Jan 2005 A1
20050159771 Petersen Jul 2005 A1
20050177103 Hunter et al. Aug 2005 A1
20050251200 Porter Nov 2005 A1
20060052816 Bates et al. Mar 2006 A1
20060058735 Lesh Mar 2006 A1
20060064151 Gutterman et al. Mar 2006 A1
20060106421 Teoh May 2006 A1
20060155323 Porter et al. Jul 2006 A1
20060155367 Hines Jul 2006 A1
20060167494 Suddaby Jul 2006 A1
20060247572 McCartney Nov 2006 A1
20070088387 Eskridge et al. Apr 2007 A1
20070106311 Wallace et al. May 2007 A1
20070208376 Meng Jun 2007 A1
20070162071 Burkett et al. Jul 2007 A1
20070167876 Euteneuer et al. Jul 2007 A1
20070173928 Morsi Jul 2007 A1
20070186933 Domingo Aug 2007 A1
20070191884 Eskridge et al. Aug 2007 A1
20070233188 Hunt Oct 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070288083 Hines Dec 2007 A1
20080097495 Feller, III et al. Apr 2008 A1
20080103505 Fransen May 2008 A1
20080281350 Sepetka et al. Nov 2008 A1
20090036877 Nardone et al. Feb 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090099647 Glimsdale Apr 2009 A1
20090227983 Griffin et al. Sep 2009 A1
20090281557 Sander et al. Nov 2009 A1
20090287291 Becking et al. Nov 2009 A1
20090287297 Cox Nov 2009 A1
20090318941 Sepetka Dec 2009 A1
20100023046 Heidner et al. Jan 2010 A1
20100023048 Mach Jan 2010 A1
20100063573 Hijlkema Mar 2010 A1
20100063582 Rudakov Mar 2010 A1
20100069948 Veznedaroglu et al. Mar 2010 A1
20100168781 Berenstein Jul 2010 A1
20100211156 Linder et al. Aug 2010 A1
20100324649 Mattsson et al. Dec 2010 A1
20110046658 Conner et al. Feb 2011 A1
20110054519 Neuss Mar 2011 A1
20110112588 Linderman et al. May 2011 A1
20110137317 O'Halloran et al. Jun 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110196413 Wallace Aug 2011 A1
20110319978 Schaffer Dec 2011 A1
20120010644 Sideris et al. Jan 2012 A1
20120071911 Sadasivan Mar 2012 A1
20120165732 Müller Jun 2012 A1
20120191123 Brister et al. Jul 2012 A1
20120283768 Cox et al. Nov 2012 A1
20120310270 Murphy Dec 2012 A1
20120323267 Ren Dec 2012 A1
20120330341 Becking et al. Dec 2012 A1
20130035665 Chu Feb 2013 A1
20130035712 Theobald et al. Feb 2013 A1
20130066357 Aboytes et al. Mar 2013 A1
20130079864 Boden Mar 2013 A1
20130110066 Sharma et al. May 2013 A1
20130204351 Cox et al. Aug 2013 A1
20130211495 Halden et al. Aug 2013 A1
20130261658 Lorenzo et al. Oct 2013 A1
20130261730 Bose et al. Oct 2013 A1
20130274863 Cox et al. Oct 2013 A1
20130345738 Eskridge Dec 2013 A1
20140005714 Quick et al. Jan 2014 A1
20140012307 Franano et al. Jan 2014 A1
20140012363 Franano et al. Jan 2014 A1
20140018838 Franano et al. Jan 2014 A1
20140135812 Divino et al. May 2014 A1
20140200607 Sepetka et al. Jul 2014 A1
20140257360 Keillor Sep 2014 A1
20140277013 Sepetka et al. Sep 2014 A1
20140358178 Hewitt et al. Dec 2014 A1
20150057703 Ryan et al. Feb 2015 A1
20150209050 Aboytes et al. Jul 2015 A1
20150272589 Lorenzo Oct 2015 A1
20150313605 Griffin Nov 2015 A1
20150342613 Aboytes et al. Dec 2015 A1
20150374483 Janardhan et al. Dec 2015 A1
20160022445 Ruvalcaba et al. Jan 2016 A1
20160030050 Franano et al. Feb 2016 A1
20160192912 Kassab Jul 2016 A1
20160249934 Hewitt et al. Sep 2016 A1
20170007264 Cruise et al. Jan 2017 A1
20170007265 Guo et al. Jan 2017 A1
20170020670 Murray et al. Jan 2017 A1
20170020700 Bienvenu et al. Jan 2017 A1
20170027640 Kunis et al. Feb 2017 A1
20170027692 Bonhoeffer et al. Feb 2017 A1
20170027725 Argentine Feb 2017 A1
20170035436 Morita Feb 2017 A1
20170035567 Duffy Feb 2017 A1
20170042548 Lam Feb 2017 A1
20170049596 Schabert Feb 2017 A1
20170071737 Kelley Mar 2017 A1
20170072452 Monetti et al. Mar 2017 A1
20170079661 Bardsley et al. Mar 2017 A1
20170079662 Rhee et al. Mar 2017 A1
20170079671 Morero et al. Mar 2017 A1
20170079680 Bowman Mar 2017 A1
20170079717 Walsh et al. Mar 2017 A1
20170079766 Wang et al. Mar 2017 A1
20170079767 Leon-Yip Mar 2017 A1
20170079812 Lam et al. Mar 2017 A1
20170079817 Sepetka et al. Mar 2017 A1
20170079819 Pung et al. Mar 2017 A1
20170079820 Lam et al. Mar 2017 A1
20170086851 Wallace et al. Mar 2017 A1
20170086996 Peterson et al. Mar 2017 A1
20170095259 Tompkins et al. Apr 2017 A1
20170100126 Bowman et al. Apr 2017 A1
20170100141 Morero et al. Apr 2017 A1
20170100143 Granfield Apr 2017 A1
20170100183 Iaizzo et al. Apr 2017 A1
20170113023 Steingisser et al. Apr 2017 A1
20170114350 dos Santos et al. Apr 2017 A1
20170147765 Mehta May 2017 A1
20170151032 Loisel Jun 2017 A1
20170165062 Rothstein Jun 2017 A1
20170165065 Rothstein et al. Jun 2017 A1
20170165454 Tuohy et al. Jun 2017 A1
20170172581 Bose et al. Jun 2017 A1
20170172766 Vong et al. Jun 2017 A1
20170172772 Khenansho Jun 2017 A1
20170189033 Sepetka et al. Jul 2017 A1
20170189035 Porter Jul 2017 A1
20170215902 Leynov et al. Aug 2017 A1
20170216484 Cruise et al. Aug 2017 A1
20170224350 Shimizu et al. Aug 2017 A1
20170224355 Bowman et al. Aug 2017 A1
20170224467 Piccagli et al. Aug 2017 A1
20170224511 Dwork et al. Aug 2017 A1
20170224953 Tran et al. Aug 2017 A1
20170231749 Perkins et al. Aug 2017 A1
20170252064 Staunton Sep 2017 A1
20170265983 Lam et al. Sep 2017 A1
20170281192 Tieu et al. Oct 2017 A1
20170281331 Perkins et al. Oct 2017 A1
20170281344 Costello Oct 2017 A1
20170281909 Northrop et al. Oct 2017 A1
20170281912 Melder et al. Oct 2017 A1
20170290593 Cruise et al. Oct 2017 A1
20170290654 Sethna Oct 2017 A1
20170296324 Argentine Oct 2017 A1
20170296325 Marrocco et al. Oct 2017 A1
20170303939 Greenhalgh et al. Oct 2017 A1
20170303942 Greenhalgh et al. Oct 2017 A1
20170303947 Greenhalgh et al. Oct 2017 A1
20170303948 Wallace et al. Oct 2017 A1
20170304041 Argentine Oct 2017 A1
20170304097 Corwin et al. Oct 2017 A1
20170304595 Nagasrinivasa et al. Oct 2017 A1
20170312109 Le Nov 2017 A1
20170312484 Shipley et al. Nov 2017 A1
20170316561 Helm et al. Nov 2017 A1
20170319826 Bowman et al. Nov 2017 A1
20170333228 Orth et al. Nov 2017 A1
20170333236 Greenan Nov 2017 A1
20170333678 Bowman et al. Nov 2017 A1
20170340333 Badruddin et al. Nov 2017 A1
20170340383 Bloom et al. Nov 2017 A1
20170348014 Wallace et al. Dec 2017 A1
20170348514 Guyon et al. Dec 2017 A1
20180140305 Connor May 2018 A1
20180242979 Lorenzo Aug 2018 A1
20180303531 Sanders et al. Oct 2018 A1
20180338767 Dasnurkar Nov 2018 A1
20190008522 Lorenzo Jan 2019 A1
20190223878 Lorenzo et al. Jan 2019 A1
20190110796 Jayaraman Apr 2019 A1
20190192162 Lorenzo Jun 2019 A1
20190192167 Lorenzo Jun 2019 A1
20190192168 Lorenzo Jun 2019 A1
20190223879 Jayaraman Jul 2019 A1
20190223881 Hewitt et al. Sep 2019 A1
20190328398 Lorenzo Oct 2019 A1
20190365385 Gorochow et al. Dec 2019 A1
20200268365 Hebert et al. Aug 2020 A1
Foreign Referenced Citations (96)
Number Date Country
2395796 Jul 2001 CA
2 431 594 Sep 2002 CA
2598048 May 2008 CA
204 683 687 Jul 2015 CN
102008015781 Oct 2009 DE
102010053111 Jun 2012 DE
102009058132 Jul 2014 DE
10 2013 106031 Dec 2014 DE
202008018523 Apr 2015 DE
102011102955 May 2018 DE
902704 Mar 1999 EP
1054635 Nov 2000 EP
1295563 Mar 2003 EP
1441649 Aug 2004 EP
1483009 Dec 2004 EP
1527753 May 2005 EP
1569565 Sep 2005 EP
1574169 Sep 2005 EP
1494619 Jan 2006 EP
1633275 Mar 2006 EP
1659988 May 2006 EP
1725185 Nov 2006 EP
1862122 Dec 2007 EP
1923005 May 2008 EP
2063791 Jun 2009 EP
2134263 Dec 2009 EP
2157937 Mar 2010 EP
2266456 Dec 2010 EP
2324775 May 2011 EP
2367482 Sep 2011 EP
2387951 Nov 2011 EP
2460476 Jun 2012 EP
2468349 Jun 2012 EP
2543345 Jan 2013 EP
2567663 Mar 2013 EP
2617386 Jul 2013 EP
2623039 Aug 2013 EP
2647343 Oct 2013 EP
2848211 Mar 2015 EP
2854704 Apr 2015 EP
2923674 Sep 2015 EP
2926744 Oct 2015 EP
3146916 Mar 2017 EP
3501429 Jun 2019 EP
3517055 Jul 2019 EP
H04-47415 Apr 1992 JP
H07-37200 Jul 1995 JP
2006-509578 Mar 2006 JP
2013-509972 Mar 2013 JP
2013537069 Sep 2013 JP
2016-502925 Feb 2015 JP
WO 9641589 Dec 1996 WO
WO 9905977 Feb 1999 WO
WO 9908607 Feb 1999 WO
WO 9930640 Jun 1999 WO
WO 2003073961 Sep 2003 WO
WO 03086240 Oct 2003 WO
2005020822 Mar 2005 WO
2005074814 Aug 2005 WO
WO 2005117718 Dec 2005 WO
WO 2006034149 Mar 2006 WO
WO 2006052322 May 2006 WO
2007076480 Jul 2007 WO
WO 2008150346 Dec 2008 WO
WO 2008151204 Dec 2008 WO
WO 2009048700 Apr 2009 WO
WO 2009105365 Aug 2009 WO
WO 2009132045 Oct 2009 WO
WO 2009135166 Nov 2009 WO
WO 2010030991 Mar 2010 WO
WO 2011057002 May 2011 WO
WO 2012032030 Mar 2012 WO
2012099704 Jul 2012 WO
WO 2012099909 Jul 2012 WO
WO 2012113554 Aug 2012 WO
WO 2013016618 Jan 2013 WO
WO 2013025711 Feb 2013 WO
WO 2013109309 Jul 2013 WO
WO 2013159065 Oct 2013 WO
WO 2013162817 Oct 2013 WO
WO 2014029835 Feb 2014 WO
WO 2014078286 May 2014 WO
WO 2014110589 Jul 2014 WO
WO 2014137467 Sep 2014 WO
WO 2015073704 May 2015 WO
WO 2015160721 Oct 2015 WO
WO 2015166013 Nov 2015 WO
WO 2015171268 Nov 2015 WO
WO 2015184075 Dec 2015 WO
WO 2015187196 Dec 2015 WO
WO 2016044647 Mar 2016 WO
WO 2016107357 Jul 2016 WO
WO 2016137997 Sep 2016 WO
WO 2017161283 Sep 2017 WO
WO 2018051187 Mar 2018 WO
WO 2012034135 Mar 2021 WO
Non-Patent Literature Citations (4)
Entry
Extended European Search Report issued in corresponding European Patent Application No. 19 21 5277 dated May 12, 2020.
Extended European Search Report issued in corresponding European Patent Application No. 20 15 5664 dated Mar. 30, 2020.
Altes et al., Creation of Saccular Aneurysms in the Rabbit: A Model Suitable for Testing Endovascular Devices. AJR 2000; 174: 349-354.
Schaffer, Advanced Materials & Processes, Oct. 2002, pp. 51-54.
Related Publications (1)
Number Date Country
20200246016 A1 Aug 2020 US